Tarun Sharma, MD, a rheumatologist with the Allegheny Health Network who helped author the American College of Rheumatology's most recent gout guidelines, sits down to provide perspective on the latest updates in gout from 2022, including new trial data, regulatory news and updates, and a glimpse into what he is most excited for in 2023.
Take 5 minutes to catch up on Rheumatology Network's highlights from the American College of Rheumatology Convergence 2022.
There was also a reduction in ultrasound features of gout at the knee identified, with improvement found in 63% of the tight control group and 14% of the conventional group.
Exposure to more than 100 mg was linked to significantly lower odds ratios for first-ever ACS event for women.
Gout, if left untreated, can lead to flares that can increase the likelihood of depression and anxiety.
Abdul Abdellatif, MD, FASN, explains the results of the MIRROR RCT trial, in which the renal function of patients with gout receiving pegloticase plus methotrexate co-therapy was evaluated.
"It may be important to identify genetic variants from a gout genome-wide association study (GWAS) rather than serum urate GWAS, in case these variants have an effect on gout independent of their effect on serum urate.”
Investigators concluded febuxostat should still be used cautiously for patients with gout and cardiovascular diseases due to inconclusive results.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 15, 2022.
Supplementation with probiotics was shown to improve hyperuricemia and symptoms of gout, among other inflammatory diseases.
“Importantly, several different immunomodulation agents may be effective for increasing treatment response rates and seem well tolerated by patients with uncontrolled gout."
Drs Orrin M. Troum and Jeff R. Peterson discuss infusion reactions associated with pegloticase and the impact of immunomodulators when used with pegloticase in gout.
Orrin M. Troum, MD, and Jeff R. Peterson, MD, discuss challenges with gout treatment.
Orrin M. Troum, MD, discusses methods and results of the MIRROR study in gout.
Results were based on the phase 4 MIRROR trial, which analyzed differences in treatment response for concomitant therapy compared with placebo in adults with uncontrolled gout.
Orrin M. Troum, MD, discusses the background to the MIRROR study in gout.
Orrin M. Troum, MD, and Jeff R. Peterson, MD, discuss burden, treatment landscape, and unmet needs in gout.
Demographic factors and comorbidities are associated with death related to COVID-19 in the general population and in people with rheumatic diseases, including gout.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 20, 2022.
“These observations suggest that the often-observed epidemiologic correlation between low serum urate and adverse health outcomes may be confounded."
Despite gout being largely associated with White men, new data suggest gout and hyperuricemia impart a larger burden on other demographic groups, including Black men, Black women, and White women.
"COVID-19 vaccines are effective against severity of SARS-COV-2 infection, but there has been a concern regarding their effect on the risk of flares in patients with gout, which are associated with health-related quality of life, healthcare resource utilization, and work productivity."
Dr. John Botson explains that gout is not a patient problem, it's a disease problem, and it needs to be approached as a lifelong rheumatic disease as opposed to an episodic one.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 16, 2022.
Investigator Dr. John Botson spoke on the phase 4 MIRROR study that supported the FDA approval for pegloticase combined with methotrexate for patients with uncontrolled gout.
